Document:

Exhibit 10.1

 

 

 

EXTENSION
AND THIRD AMENDING AGREEMENT TO NAME AND LIKENESS AND LICENSE AGREEMENT

This Extension and Third Amending Agreement
to Name and Likeness and License Agreement (this “Extension ‎Agreement”) is made to effective as of August 31,
2022 (“Effective Date”), by and between Leeland ‎& Sig LLC d/b/a Stanley Brothers Brand Company, a Colorado
limited liability company ‎‎(“Licensor”), Charlotte's Web, Inc., a Delaware corporation (“CWB”),
and Charlotte's Web ‎Holdings, Inc., a British Columbia corporation (“Pubco” and together with CWB, the “Licensees”).
‎Licensor and Licensees shall be referred to herein collectively as the “Parties” and each may be ‎referred
to individually as a “Party.”‎

RECITALS

WHEREAS the Licensor,
CWB Holdings, Inc. and Pubco entered into a Name and Likeness ‎and License Agreement dated August 1, 2018 (the “Original
Agreement”); and‎

WHEREAS on August 30,
2018, CWB Holdings, Inc. merged into Stanley Brothers Inc. ‎pursuant to a merger agreement, with the surviving entity changing its
name to Charlotte's Web, Inc. ‎and being a wholly-owned subsidiary of Pubco;

WHEREAS the Parties entered
into an Amending Agreement to Name and Likeness Agreement effective April 16, 2021 (the “First Amending Agreement”)
pursuant to which, among other amendments, the term of the Original Agreement was extended to July 31, 2022 and an Extension and Second
Amending Agreement to Name and Likeness and License Agreement (the ”Second Amending Agreement”) pursuant to which,
among other amendments, the term of the Original Agreement was extended to August 30, 2022 (the “Amended Term”); and

WHEREAS the Parties wish
to amend the Original Agreement, the First Amending Agreement and the Second Amending Agreement to extend the Amended Term;‎

NOW, THEREFORE, in consideration
of the mutual promises herein contained, it is hereby ‎agreed:‎

 

    	 

    	 

    

 

		article	1 - INTERPRETATION

1.1               
‎Incorporation of Original Agreement, First Amending Agreement and Second
Amending Agreement. This Extension Agreement is supplemental to and ‎shall be read in conjunction with the Original Agreement,
the First Amending Agreement, and the Second Amending Agreement, and the Original Agreement, the First Amending Agreement, the Second
Amending Agreement, and this Extension ‎Agreement shall have effect so far as practicable as if all the provisions thereof and hereof
were ‎contained in one document.‎

1.2               
Effect on the Original Agreement the First Amending Agreement, and the Second
Amending Agreement. Except as specifically amended in this Extension Agreement,‎ the Parties hereby confirm that the Original
Agreement, the First Amending Agreement, and the Second Amending Agreement, and their terms and conditions, are and shall ‎remain
in full force and effect and are hereby ratified. To the extent there is any inconsistency ‎between the Original Agreement, the First
Amending Agreement, the Second Amending Agreement and this Extension Agreement, the terms of this Extension ‎Agreement shall prevail
and supersede the Original Agreement, the First Amending Agreement, and the Second Amending Agreement.‎ 

1.3               
Defined Terms. All terms used but not defined herein shall find
their meaning in the ‎Original Agreement.‎

		article	2 - EFFECTIVE DATE OF AMENDMENTS

2.1               
The amendments contained in this Extension Agreement shall become effective as
of the Effective Date of this Extension Agreement.‎

		article	3 - AMENDMENTS

3.1               
Section 8(a) of the Original Agreement shall be deleted in its entirety and replaced
with the ‎following:‎

“(a) Term. Unless otherwise terminated
in accordance with the provisions of this ‎Section 8, this Agreement shall commence on the Effective Date and shall terminate ‎on
September 30, 2022 (the “Term”).”‎,

3.2               
‎Section 3.14 of the First Amending Agreement shall be deemed superseded by
Section 3.1 of this Extension Agreement.

3.3               
Section 3.1 of the Second Amending Agreement shall be deemed superseded by Section
3.1 of this Extension Agreement. 

		article	4 - MISCELLANEOUS

4.1               
Further Assurances. The Parties hereto shall from time to time do
all such further acts and ‎things and execute and deliver all such documents as are required in order to effect the full intent of
and ‎fully perform and carry out the terms of this Extension Agreement.‎

4.2               
Inurement. This Extension Agreement shall inure to the benefit of
and shall be binding ‎upon the Parties hereto and their respective successors and permitted assigns.‎

4.3               
Counterparts. This Extension Agreement may be executed in any number
of counterparts ‎and delivered by facsimile or electronic mail and all such counterparts taken together shall be ‎deemed to constitute
one and the same instrument.‎

4.4               
Whole Agreement; Only Written Amendments. The Original
Agreement, the First Amending Agreement and the Second Amending Agreement (as amended ‎hereby) and this Extension Agreement constitute
the whole and entire agreement between the ‎Parties hereto regarding the subject matter hereof and thereof and cancel and supersede
any prior ‎agreements, undertakings, declarations, commitments, representations, written or oral, in respect ‎thereof. Any provision
of this Extension Agreement may only be amended if the Parties so agree in ‎writing.‎

4.5               
Time. Time is of the essence for all purposes of this Extension
Agreement.‎

 

‎[THE REMAINDER OF THIS PAGE IS INTENTIONALLY
LEFT BLANK‎]

 

    	 

    	 

    

 

IN WITNESS WHEREOF the Parties have executed
this Extension Agreement as of the date first written above.

	Licensees:	 	Licensor:
	Charlotte’s Web, Inc.

By:/s/ Jacques Tortoroli

      Name:  Jacques Tortoroli

      Title:    CEO, Director	 	Leeland & Sig LLC d/b/a/ Stanley Brothers Brand Holding Co

By:/s/ Jesse Stanley

      Name:  Jesse Stanley

      Title:    Board of Managers
	Charlotte’s Web Holdings, Inc.

By:/s/ Jacques Tortoroli

      Name:  Jacques Tortoroli

       Title:    CEO, DirectorExhibit
10.1

 

BLINK
CHARGING CO.

 

$250,000,000

Common
Stock

($0.001
par value per share)

 

Sales
Agreement

 

September
2, 2022

 

Barclays
Capital Inc.

745
Seventh Avenue

New
York, New York 10019

 

BofA
Securities, Inc.

One
Bryant Park

New
York, New York 10036

 

HSBC
Securities (USA) Inc.

452
Fifth Avenue

New
York, New York 10018

 

H.C.
Wainwright & Co., LLC

430
Park Avenue

New
York, New York 10022

 

Roth
Capital Partners, LLC

888
San Clemente Drive, Suite 400

Newport
Beach, CA 92660

 

ThinkEquity
LLC

17
State Street, 41st Floor

New
York, New York 10004

 

Ladies
and Gentlemen:

 

Blink
Charging Co., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with
Barclays Capital Inc., BofA Securities, Inc., HSBC Securities (USA) Inc., H.C. Wainwright & Co., LLC, Roth Capital Partners, LLC
and ThinkEquity LLC (each, an “Agent,” and together, the “Agents”), as follows:

 

1.
Issuance and Sale of Shares. The Company agrees
that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue
and sell through or to the Agents, shares (the “Placement Shares”) of common stock of the Company, $0.001 par value
per share (the “Common Stock”) having an aggregate offering price of up to $250,000,000, provided, however,
that in no event shall the Company issue or sell through Agents such number of Placement Shares that (a) exceeds the number or dollar
amount of shares of Common Stock that may be sold pursuant to the Registration Statement (as defined below), or (b) exceeds the number
of authorized but unissued shares of Common Stock of the Company (the “Maximum Amount”). Notwithstanding anything
to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 1 on
the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that the Agents
shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through or to the Agents will
be effected pursuant to the Registration Statement (as defined below) filed by the Company and declared effective by the Securities and
Exchange Commission (the “Commission”), although nothing in this Agreement shall be construed as requiring the Company
to use the Registration Statement to issue any Placement Shares.

 

    	 

     

    

 

The
Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder
(the “Securities Act”), with the Commission a registration statement on Form S-3 (File No. 333-251919), including
a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and
which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities
Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”). The Company will
prepare a prospectus supplement specifically relating to the Placement Shares (the “Prospectus Supplement”) to the
base prospectus included as part of such registration statement. The Company will furnish to the Agents, for use by the Agents, copies
of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement
Shares. Except where the context otherwise requires, such registration statement, and any post-effective amendment thereto, including
all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as
defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such
registration statement pursuant to Rule 430B of the Securities Act, or any subsequent registration statement on Form S-3 filed pursuant
to Rule 415(a)(6) under the Securities Act by the Company to cover any Placement Shares, is herein called the “Registration
Statement.” The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement,
as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently
been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any then issued Issuer
Free Writing Prospectus (defined below), is herein called the “Prospectus.” Any reference herein to the Registration
Statement, the Prospectus or any amendment or supplement thereto, shall be deemed to refer to and include the documents incorporated
or deemed to be incorporated by reference therein, and any reference herein to the terms “amend,” “amendment”
or “supplement” with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the
filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein (the “Incorporated
Documents”). For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment
or supplement thereto shall be deemed to include any copy filed with the Commission pursuant to its Electronic Data Gathering Analysis
and Retrieval System, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively,
“EDGAR”).

 

2.
Placements. Each time that the Company wishes
to issue and sell Placement Shares hereunder (each, a “Placement”), it will notify the Designated Agent (as defined
below) by email notice (or other method mutually agreed to in writing by the parties) of the number or dollar value of Placement Shares,
the time period during which sales are requested to be made, any limitation on the number of Placement Shares that may be sold in any
one day and any minimum price below which sales may not be made (a “Placement Notice”), the form of which is attached
hereto as Schedule 1. The Placement Notice shall originate from any of the individuals from the Company set forth on Schedule
3 (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the
individuals from the Designated Agent set forth on Schedule 3, as such Schedule 3 may be amended from time to time. The
Placement Notice shall be effective unless and until (i) the Designated Agent declines to accept the terms contained therein for any
reason, in its sole discretion, by promptly notifying the Company, (ii) the entire amount of the Placement Shares thereunder have been
sold, (iii) the Company suspends or terminates the Placement Notice or (iv) the Agreement has been terminated under the provisions of
Section 12. The amount of any discount, commission or other compensation to be paid by the Company to each Designated Agent in
connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in Schedule 2. It
is expressly acknowledged and agreed that neither the Company nor the Designated Agent will have any obligation whatsoever with respect
to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Designated Agent and the Designated
Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and
herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement
Notice will control. As used herein, “Designated Agent” shall mean, with respect to any Placement Notice, the specific
Agent selected by the Company to act as sales agent, provided that such Agent selected by the Company has agreed to act as sales agent.

 

3.
Sale of Placement Shares by the Agents. Subject
to the provisions of Section 5(a), the Designated Agent, for the period specified in the Placement Notice, will use its commercially
reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations
and the rules of the Nasdaq Capital Market (the “Exchange”), to sell the Placement Shares up to the amount specified,
and otherwise in accordance with the terms of such Placement Notice. The Designated Agent will provide written confirmation to the Company
no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement
Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable by the Company to the Designated
Agent pursuant to Section 2 with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an
itemization of the deductions made by the Designated Agent (as set forth in Section 5(b)) from the gross proceeds that it receives
from such sales. Subject to the terms of the Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed
to be an “at the market offering” as defined in Rule 415 of the Securities Act.

 

    	2

     

    

 

4.
Suspension of Sales.

 

(a)
The Company or the Designated Agent may, upon notice to the other party in writing (including by email correspondence to each of the
individuals of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged by any of the
individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission
or email correspondence to each of the individuals of the other party set forth on Schedule 3), suspend any sale of Placement
Shares; provided, however, that such suspension shall not affect or impair any party’s obligations with respect to
any Placement Shares sold hereunder prior to the receipt of such notice. Each party agrees that no such notice under this Section
4 shall be effective against any other party unless it is made to one of the individuals named on Schedule 3 hereto, as such
Schedule may be amended from time to time.

 

(b)
Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material non-public
information, the Company and the Agents agree that (i) no sale of Placement Shares will take place, (ii) the Company shall not request
the sale of any Placement Shares, and (iii) no Agents shall be obligated to sell or offer to sell any Placement Shares.

 

(c)
If either party has reason to believe that the exemptive provisions set forth in Rule 101(c)(1) of Regulation M under the Exchange Act
(applicable to securities with an average daily trading volume of $1,000,000 that are issued by an issuer whose common equity securities
have a public float value of at least $150,000,000) are not satisfied with respect to the Company or the Placement Shares, it shall promptly
notify the other party and sales of Placement Shares under this Agreement shall be suspended until that or other exemptive provisions
have been satisfied in the judgment of each party.

 

5.
Sale and Delivery to the Agent; Settlement.

 

(a)
Sale of Placement Shares. On the basis of the representations and warranties herein contained and subject to the terms
and conditions herein set forth, upon the Designated Agent’s acceptance of the terms of a Placement Notice, and unless the sale
of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this
Agreement, the Designated Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent
with its normal trading and sales practices to sell such Placement Shares up to the amount specified in such Placement Notice, and otherwise
in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that the
Designated Agent will be successful in selling Placement Shares, (ii) the Designated Agent will incur no liability or obligation to the
Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Designated Agent
to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations
to sell such Placement Shares as required under this Agreement and (iii) the Designated Agent shall be under no obligation to purchase
Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by the Designated Agent and the Company.

 

    	3

     

    

 

(b)
Settlement of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of
Placement Shares will occur on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading)
following the date on which such sales are made (each, a “Settlement Date”). The amount of proceeds to be delivered
to the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be equal
to the aggregate sales price received by the Designated Agent, after deduction for (i) the Designated Agent’s commission, discount
or other compensation for such sales payable by the Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed
by any governmental or self-regulatory organization in respect of such sales.

 

(c)
Delivery of Placement Shares. On each Settlement Date, against payment of the Net Proceeds, the Company will, or will cause its
transfer agent to, electronically transfer the Placement Shares being sold by crediting the Designated Agent’s or its designee’s
account (provided the Designated Agent shall have given the Company written notice of such designee prior to the Settlement Date)
at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually
agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form.
On each Settlement Date, the Designated Agent will deliver the related Net Proceeds in same day funds to an account designated by the
Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults
in its obligation to deliver Placement Shares on a Settlement Date, the Company agrees that in addition to and in no way limiting the
rights and obligations set forth in Section 10(a) hereto, it will (i) hold the Designated Agent harmless against any loss, claim,
damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by
the Company or its transfer agent (if applicable) and (ii) pay to the Agent any commission, discount, or other compensation to which
it would otherwise have been entitled absent such default.

 

(d)
Limitations on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement
Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant
to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount,
(B) the amount available for offer and sale under the Registration Statement and (C) the amount authorized from time to time to be issued
and sold under this Agreement by the Company’s board of directors, a duly authorized committee thereof or a duly authorized executive
committee, and notified to the Agents in writing. Under no circumstances shall the Company cause or request the offer or sale of any
Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company’s
board of directors, duly authorized committee thereof or a duly authorized executive committee, and notified to the Agents in writing.
Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares sold pursuant to
this Agreement to exceed the Maximum Amount.

 

    	4

     

    

 

6.
Representations and Warranties of the Company.
Except as disclosed in the Registration Statement or Prospectus (including the Incorporated Documents), the Company represents and warrants
to, and agrees with the Agents that as of the date of this Agreement and as of each Applicable Time (as defined below), unless such representation,
warranty or agreement specifies a different date or time:

 

(a)
Registration Statement and Prospectus. The Company and the transactions contemplated by this Agreement meet the requirements for
and comply with the conditions for the use of Form S-3 under the Securities Act. The Registration Statement has been filed with the Commission
and declared effective under the Securities Act. The Prospectus Supplement will name the Agent as the agent in the section entitled “Plan
of Distribution.” The Company has not received, and has no notice of, any order of the Commission preventing or suspending the
use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement and the offer
and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material
respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be described in the Registration
Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been so described or filed. Copies of the Registration
Statement, the Prospectus, and any such amendments or supplements and all documents incorporated by reference therein that were filed
with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to Agent and its counsel.
The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the Placement
Shares, will not distribute any offering material in connection with the offering or sale of the Placement Shares other than the Registration
Statement and the Prospectus and any Issuer Free Writing Prospectus to which Agent has consented, such consent shall not be unreasonably
withheld, conditioned or delayed. The Company has not, in the 12 months preceding the date hereof, received notice from the Exchange
to the effect that the Company is not in compliance with the listing or maintenance requirements. The Company has no reason to believe
that it will not in the foreseeable future continue to be in compliance with all such listing and maintenance requirements.

 

(b)
No Misstatement or Omission. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment
or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects
with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date,
will conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. The Prospectus and any amendment or supplement thereto, on the date
thereof and at each Applicable Time (defined below), did not and will not include an untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The
Incorporated Documents did not, and any further documents filed and incorporated by reference therein will not, when filed with the Commission,
contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or necessary to
make the statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not
apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished to
the Company by Agent specifically for use in the preparation thereof, which information shall be limited to the ninth paragraph of the
Prospectus Supplement section titled “Plan of Distribution” (such information, the “Agent Information”).

 

    	5

     

    

 

(c)
Conformity with Securities Act and Exchange Act. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus
or any amendment or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under
the Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed and will
conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.

 

(d)
Financial Information. The financial statements of each of the Company, its subsidiaries and SemaConnect, Inc., a Delaware corporation
(“SemaConnect”) included or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing
Prospectuses, if any, together with the related notes and schedules, present fairly, in all material respects, the financial position
of such entities as of the dates indicated and the results of operations, cash flows and changes in stockholders’ equity of such
entities for the periods specified and have been prepared in compliance with the requirements of the Securities Act and Exchange Act
and in conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a consistent
basis (except for (i) such adjustments to accounting standards and practices as are noted therein, (ii) in the case of unaudited interim
financial statements, to the extent such financial statements may not include footnotes required by GAAP or may be condensed or summary
statements and (iii) such adjustments which will not be material, either individually or in the aggregate) during the periods involved;
the other financial and statistical data with respect to such entities contained or incorporated by reference in the Registration Statement,
the Prospectus and the Issuer Free Writing Prospectuses, if any, are accurately and fairly presented and prepared on a basis consistent
with the financial statements and books and records of such entities; there are no financial statements (historical or pro forma) that
are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated
by reference as required; neither the Company nor SemaConnect has any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement and the Prospectus (including all disclosure contained
or incorporated by reference in the Registration Statement or Prospectus); and all disclosures contained or incorporated by reference
in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, regarding “non-GAAP financial measures”
(as such term is defined by the rules and regulations of the Commission) comply in all material respects with Regulation G of the Exchange
Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The pro forma financial statements included or
incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, include assumptions
that provide a reasonable basis for presenting the significant effects directly attributable to the transactions and events described
therein, the related pro forma adjustments give appropriate effect to those assumptions, and the pro forma adjustments reflect the proper
application of those adjustments to the historical financial statement amounts in the pro forma financial statements included or incorporated
by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any. The pro forma financial
statements included or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses,
if any, comply as to form in all material respects with the applicable requirements of Regulation S-X under the Act.

 

(e)
Conformity with EDGAR Filing. The Prospectus delivered to the Agent for use in connection with the sale of the Placement Shares
pursuant to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing
via EDGAR, except to the extent permitted by Regulation S-T.

 

    	6

     

    

 

(f)
Organization. The Company and each of its subsidiaries have been duly organized, is validly existing as a corporation and in good
standing as a corporation or other business entity under the laws of its jurisdiction of organization. The Company and each of its subsidiaries
is, and will be, duly licensed or qualified as a foreign corporation for transaction of business and in good standing under the laws
of each other jurisdiction in which its ownership or lease of property or the conduct of its business requires such license or qualification,
and has all corporate power and authority necessary to own or hold its properties and to conduct its business as described in the Registration
Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not,
individually or in the aggregate, have a material adverse effect on or affecting the assets, business, operations, earnings, properties,
condition (financial or otherwise), prospects, stockholders’ equity or results of operations of the Company or prevent or materially
interfere with consummation of the transactions contemplated hereby (a “Material Adverse Effect”).

 

(g)
Subsidiaries. The Company does not own or control, directly or indirectly, any corporation, association or other entity, other
than the subsidiaries listed in Exhibit 21.1 to the Company’s Annual Report on Form 10-K for the most recently ended fiscal year
and SemaConnect, LLC. The Company owns directly or indirectly, all of the equity interests of its subsidiaries free and clear of any
lien, charge, security interest, encumbrance, right of first refusal or other restriction, and all the equity interests of its subsidiaries
are validly issued and are fully paid, non-assessable and free of preemptive and similar rights.

 

(h)
No Violation or Default. The Company is not, and the issuance and sale of Placement Shares by the Company will not result, (i)
in violation of its charter or by-laws or similar organizational documents of the Company and its subsidiaries; (ii) in default, and
no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance
of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument
to which the Company or any of its subsidiaries is a party or by which the Company is bound or to which any of the property or assets
of the Company is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default
that would not, individually or in the aggregate, have a Material Adverse Effect. To the Company’s knowledge, no other party under
any material contract or other agreement to which it is a party is in default in any respect thereunder where such default would have
a Material Adverse Effect.

 

(i)
No Material Adverse Effect. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Prospectus and the Issuer Free Writing Prospectuses, if any, (including any document deemed incorporated by reference therein), there
has not been (i) any Material Adverse Effect, (ii) any transaction which is material to the Company, (iii) any obligation or liability,
direct or contingent (including any off-balance sheet obligations), incurred by the Company which is material to the Company, (iv) any
material change in the capital stock or outstanding long-term indebtedness (other than (A) the grant of additional awards under equity
incentive plans, (B) changes in the number of outstanding Common Stock due to the issuance of shares upon exercise or conversion of securities
exercisable for or convertible into Common Stock outstanding on the date hereof, (C) any repurchase of capital stock of the Company,
(D) as a result of the sale of Placement Shares, or (E) other than as publicly reported or announced), or (v) any dividend or distribution
of any kind declared, paid or made on the capital stock of the Company other than in each case above in the ordinary course of business
or as otherwise disclosed in the Registration Statement or Prospectus (including any document deemed incorporated by reference therein).

 

    	7

     

    

 

(j)
Capitalization. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and
non-assessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights,
rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than the grant of additional options and restricted stock units
under the Company’s existing stock option plans, or changes in the number of outstanding shares of Common Stock of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding
on the date hereof or due to issuances of shares of Common Stock as otherwise publicly reported or announced) and such authorized capital
stock conforms to the description thereof set forth in the Registration Statement and the Prospectus. The description of the securities
of the Company in the Registration Statement and the Prospectus is complete and accurate in all material respects. As of the date referred
to therein, the Company does not have outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities
or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or
other securities.

 

(k)
Authorization; Enforceability. The Company has full legal right, power and authority to enter into this Agreement and perform
the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal,
valid and binding agreement of the Company enforceable in accordance with its terms, except (i) to the extent that enforceability may
be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general
equitable principles and (ii) the indemnification and contribution provisions of Section 10 hereof may be limited by federal or
state securities laws and public policy considered in respect thereof.

 

(l)
Authorization of Placement Shares. The Placement Shares, when issued and delivered pursuant to the terms approved by the board
of directors of the Company or a duly authorized committee thereof, against payment therefor as provided herein, will be duly and validly
authorized and issued and fully paid and non-assessable, free and clear of any pledge, lien, encumbrance, security interest or other
claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and
will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when issued, will conform in all material respects
to the description thereof set forth in or incorporated into the Prospectus.

 

(m)
No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority having jurisdiction over the Company or its subsidiaries required for the execution, delivery
and performance by the Company this Agreement, the issuance and sale by the Company of the Placement Shares, except for such consents,
approvals, authorizations, orders and registrations or qualifications as may be required under applicable state securities laws or by
the by-laws and rules of the Financial Industry Regulatory Authority (“FINRA”) or the Exchange in connection with
the sale of the Placement Shares by the Agent.

 

    	8

     

    

 

(n)
No Preferential Rights. (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities
Act (each, a “Person”), has the right, contractual or otherwise, to cause the Company or its subsidiaries to issue
or sell to such Person any Common Stock or shares of any other capital stock or other securities of the Company, (ii) no Person has any
preemptive rights, resale rights, rights of first refusal, or any other rights (whether pursuant to a “poison pill” provision
or otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company, (iii) no Person has
the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of Common Stock, and
(iv) no Person has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common Stock
or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities in the Registration
Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the
sale of the Placement Shares as contemplated thereby or otherwise.

 

(o)
Independent Public Accountant. (i) Marcum LLP (the “Accountant”), whose report on the financial statements
of the Company is filed with the Commission as part of the Company’s Annual Report on Form 10-K for the most recently ended fiscal
year, filed with the Commission and incorporated into the Registration Statement and the Prospectus, are and, during the periods covered
by their report, were an independent registered public accounting firm with respect to the Company within the meaning of the Securities
Act and the Public Company Accounting Oversight Board (United States). To the Company’s knowledge, the Accountant is not in violation
of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) with respect
to the Company. (ii) BDO USA, LLP (the “SemaConnect Accountant”), are and, during the periods covered by their audit
report included or incorporated by reference in the Registration Statement and the Prospectus, were an independent registered public
accounting firm with respect to SemaConnect within the meaning of the Securities Act and the Public Company Accounting Oversight Board
(United States).

 

(p)
Enforceability of Agreements. All agreements between the Company and third parties expressly referenced in the Prospectus are
legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that
(i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights
generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited be federal
or state securities laws or public policy considerations in respect thereof, and except for any unenforceability that, individually or
in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

 

    	9

     

    

 

(q)
No Litigation. There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company’s
knowledge, any legal, governmental or regulatory investigations, to which the Company or its subsidiaries is a party or to which any
property of the Company or its subsidiaries is the subject that, individually or in the aggregate, if determined adversely to the Company
would have a Material Adverse Effect or materially and adversely affect the ability of the Company to perform its obligations under this
Agreement; to the Company’s knowledge, no such actions, suits or proceedings are threatened or contemplated by any governmental
or regulatory authority or threatened by others, that individually or in the aggregate, if determined adversely to the Company or its
subsidiaries, would have a Material Adverse Effect; and (i) there are no current or pending legal, governmental or regulatory investigations,
actions, suits or proceedings that are required under the Securities Act to be described in the Prospectus that are not so described;
and (ii) there are no contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration
Statement that are not so filed.

 

(r)
Licenses and Permits. The Company and each of its subsidiaries have, and are operating in compliance with, such permits, licenses,
patents, franchises, certificates of need and other approvals or authorizations of governmental or regulatory authorities (“Permits”)
as are necessary under applicable law to own their properties and conduct their businesses in the manner described in the most recent
Registration Statement and the Prospectus, except where the failure to possess, obtain or make the same would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and each of its subsidiaries have fulfilled and
performed all of their respective obligations with respect to the Permits, and no event has occurred that allows, or after notice or
lapse of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder or any such
Permits, except for any of the foregoing that could not reasonably be expected to have a Material Adverse Effect. Neither the Company
nor any of its subsidiaries has received notice of any revocation or modification of any such Permits or has any reason to believe that
any such Permits will not be renewed in the ordinary course, except where the failure to obtain any such renewal would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(s)
No Material Defaults. Neither the Company nor its subsidiaries has defaulted on any installment on indebtedness for borrowed money
or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, have a Material Adverse Effect. The
Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form
10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted on any
installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the
aggregate, could reasonably be expected to have a Material Adverse Effect.

 

(t)
S-3 Eligibility. Since the time of the initial filing of the Registration Statement, the Company has been, and continues to be,
a “well-known seasoned issuer” (as defined in Rule 405), and is eligible to use Form S-3 for the offering of the Placement
Shares. The Company was not an “ineligible issuer” (as defined in Rule 405) at any such time or date. The Registration Statement
is an “automatic shelf registration statement” (as defined in Rule 405) and was filed not earlier than the date that is three
years prior to the applicable Settlement Date.

 

(u)
Certain Market Activities. Neither the Company, its subsidiaries, nor, to the Company’s knowledge, any of its directors,
officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be
expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Placement Shares.

 

    	10

     

    

 

(v)
Broker/Dealer Relationships. Neither the Company nor any related entities (i) is required to register as a “broker”
or “dealer” in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries,
controls or is a “person associated with a member” or “associated person of a member” (within the meaning set
forth in the FINRA Manual).

 

(w)
No Reliance. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice
in connection with the offering and sale of the Placement Shares.

 

(x)
Taxes. The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed
through the date hereof, subject to permitted extensions and good faith contestations, and have paid all taxes that have become due,
and no tax deficiency has been determined adversely to the Company or any of its subsidiaries. The Company has no knowledge of any federal,
state or other governmental tax deficiencies that have been, or could reasonably be expected to be asserted against the Company, that
could, in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(y)
Title to Real and Personal Property. The Company has good and valid title in fee simple to all items of real property and good
and valid title to all personal property described in the Registration Statement or Prospectus as being owned by it that are material
to the business of the Company, in each case free and clear of all liens, encumbrances and claims, except those that (i) do not materially
interfere with the use made and proposed to be made of such property by the Company or (ii) would not reasonably expected, individually
or in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration Statement or Prospectus as being
leased by the Company is held by it under valid, existing and enforceable leases, except those that (A) do not materially interfere with
the use made or proposed to be made of such property by the Company or (B) would not be reasonably expected to have a Material Adverse
Effect.

 

(z)
Intellectual Property. The Company and each of its subsidiaries own or possess adequate rights to use all material patents, patent
applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, know-how,
inventions, domain names, software, systems and technology (including trade secrets and other unpatented and/or unpatentable proprietary
or confidential information, systems or procedures) necessary for the conduct of their respective businesses and have no reason to believe
that the conduct of their respective businesses will conflict with, and have not received any notice of any claim of conflict with, any
such rights of others.

 

    	11

     

    

 

(aa)
Environmental Laws. The Company and each of its subsidiaries (i) are, and at all times prior hereto have been, in compliance with
all applicable laws, regulations, ordinances, rules, orders, judgments, decrees, permits or other legal requirements of any governmental
authority, including without limitation any international, foreign, national, state, provincial, regional, or local authority, relating
to pollution, the protection of human health or safety, the environment, or natural resources, or to use, handling, storage, manufacturing,
transportation, treatment, discharge, disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental
Laws”) applicable to such entity, which compliance includes, without limitation, obtaining, maintaining and complying with
all permits and authorizations and approvals required by Environmental Laws to conduct their respective businesses, and (ii) have not
received notice or otherwise have knowledge of any actual or alleged violation of Environmental Laws, or of any actual or potential liability
for or other obligation concerning the presence, disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,
except in the case of clause (i) or (ii) where such non-compliance, violation, liability or other obligation would not, in the aggregate,
reasonably be expected to have a Material Adverse Effect. (x) There are no proceedings that are pending, or known to be contemplated,
against the Company or any of its subsidiaries under Environmental Laws in which a governmental authority is also a party, other than
such proceedings which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries
are not aware of any issues regarding compliance with Environmental Laws or liabilities or other obligations under Environmental Laws
or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material
effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z) neither the Company
nor any of its subsidiaries anticipate material capital expenditures relating to Environmental Laws.

 

(bb)
Internal Controls. The Company and each of its subsidiaries maintain a system of internal control over financial reporting (as
such term is defined in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been
designed by, or under the supervision of, the Company’s principal executive officer and principal financial officers, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles in the United States. The Company and each of its subsidiaries maintain internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorization, (ii) transactions are recorded as necessary to permit preparation of the Company’s financial
statements in conformity with accounting principles generally accepted in the United States and to maintain accountability for its assets,
(iii) access to the Company’s assets is permitted only in accordance with management’s general or specific authorization,
(iv) the recorded accountability for the Company’s assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences and (v) the interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the pricing disclosure package and the Prospectus fairly present the information called for in all material respects
and are prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as disclosed in the Registration
Statement or the Prospectus, as of the date of the most recent balance sheet of the Company and its consolidated subsidiaries reviewed
or audited by Marcum LLP and the audit committee of the board of directors of the Company (the “Audit Committee”),
there were no material weaknesses in the Company’s internal controls. Since the date of the most recent balance sheet of the Company
and its consolidated subsidiaries reviewed or audited by Marcum LLP and the Audit Committee, (i) the Company has not been advised of
or become aware of (A) any significant deficiencies in the design or operation of internal controls that could adversely affect the ability
of the Company or any of its subsidiaries to record, process, summarize and report financial data, or any material weaknesses in internal
controls, or (B) any fraud, whether or not material, that involves management or other employees who have a significant role in the internal
controls of the Company and each of its subsidiaries, and (ii) there have been no significant changes in internal controls or in other
factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and
material weaknesses.

 

    	12

     

    

 

(cc)
Disclosure Controls. (i) The Company and each of its subsidiaries maintain disclosure controls and procedures (as such term is
defined in Rule 13a-15(e) under the Exchange Act), (ii) such disclosure controls and procedures are designed to ensure that the information
required to be disclosed by the Company and its subsidiaries in the reports they file or submit under the Exchange Act are accumulated
and communicated to management of the Company and its subsidiaries, including their respective principal executive officers and principal
financial officers, as appropriate, to allow timely decisions regarding required disclosure to be made, and (iii) such disclosure controls
and procedures are effective in all material respects to perform the functions for which they were established.

 

(dd)
Critical Accounting Policies. The section entitled “Controls and Procedures” set forth in the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021, as incorporated by reference in the Registration Statement and the Prospectus
accurately and fully describes (i) the accounting policies that the Company believes are the most important in the portrayal of the Company’s
financial condition and results of operations and that require management’s most difficult, subjective or complex judgments (“Critical
Accounting Policies”); (ii) the judgments and uncertainties affecting the application of Critical Accounting Policies; and
(iii) the likelihood that materially different amounts would be reported under different conditions or using different assumptions and
an explanation thereof.

 

(ee)
Sarbanes-Oxley. The Company is not aware of any failure on the part of the Company or any of the Company’s directors or
officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act and the applicable rules and
regulations promulgated thereunder in all material respects. Each of the principal executive officer and the principal financial officer
of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company
as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules,
forms, statements and other documents required to be filed by it or furnished by it to the Commission during the past 12 months. For
purposes of the preceding sentence, “principal executive officer” and “principal financial officer” shall have
the meanings given to such terms in the Sarbanes-Oxley Act.

 

(ff)
Finder’s Fees. The Company has not incurred any liability for any finder’s fees, brokerage commissions or similar
payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to Agent pursuant to this
Agreement.

 

(gg)
Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the
knowledge of the Company, is threatened which would be reasonably likely to have a Material Adverse Effect.

 

    	13

     

    

 

(hh)
Investment Company Act. Neither the Company nor its subsidiaries is, or after giving effect to the offering and sale of the Placement
Shares, will be, an “investment company” or an entity “controlled” by an “investment company,” as
such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”).

 

(ii)
Off-Balance Sheet Arrangements. There are no transactions, arrangements and other relationships between and/or among the Company,
its subsidiaries and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited
to, any structural finance, special purpose or limited purpose entity (each, an “Off Balance Sheet Transaction”) that
could reasonably be expected to affect materially the Company’s liquidity or the availability of or requirements for its capital
resources, including those Off Balance Sheet Transactions described in the Commission’s Statement about Management’s Discussion
and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the
Prospectus which have not been described as required.

 

(jj)
Underwriter Agreements. Other than with respect to this Agreement, the Company is not a party to any agreement with an agent or
underwriter for any other “at the market” or continuous equity transaction.

 

(kk)
ERISA. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed to by
the Company or any of its affiliates for employees or former employees of the Company has been maintained in material compliance with
its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the
Internal Revenue Code of 1986, as amended (the “Code”); no prohibited transaction, within the meaning of Section 406
of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect to any such
plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the
funding rules of Section 412 of the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section
412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these
purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable
actuarial assumptions.

 

(ll)
Forward Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) (a “Forward Looking Statement”) contained in the Registration Statement and the Prospectus
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. The Forward Looking Statements
incorporated by reference in the Registration Statement and the Prospectus from the Company’s Annual Report on Form 10-K for the
fiscal year most recently ended (i) are within the coverage of the safe harbor for forward looking statements set forth in Section 27A
of the Securities Act, Rule 175(b) under the Securities Act or Rule 3b-6 under the Exchange Act, as applicable, (ii) were made by the
Company with a reasonable basis and in good faith and reflect the Company’s good faith commercially reasonable best estimate of
the matters described therein, and (iii) have been prepared in accordance with Item 10 of Regulation S-K under the Securities Act.

 

    	14

     

    

 

(mm)
Agent Purchases. The Company acknowledges and agrees that Agent has informed the Company that the Agent may, to the extent permitted
under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while this Agreement is in effect,
provided, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent each
Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a “riskless principal” or
in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by the
Agent.

 

(nn)
Margin Rules. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of
the Federal Reserve System or any other regulation of such Board of Governors.

 

(oo)
Insurance. The Company and each of its subsidiaries carry, or are covered by, insurance from insurers of recognized financial
responsibility in such amounts and covering such risks as the Company reasonably believes is adequate for the conduct of their respective
businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries.
All policies of insurance of the Company and its subsidiaries are in full force and effect; the Company and each of its subsidiaries
are in compliance with the terms of such policies in all material respects; and neither the Company nor any of its subsidiaries has received
notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made
in order to continue such insurance; there are no claims by the Company or any of its subsidiaries under any such policy or instrument
as to which any insurance company is denying liability or defending under a reservation of rights clause; and neither the Company nor
any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that could not reasonably
be expected to have a Material Adverse Effect.

 

(pp)
No Improper Practices. (i) Neither the Company, nor to the Company’s knowledge, any of its executive officers has, in the
past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution
in violation of law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or
foreign office or other person charged with similar public or quasi-public duty in violation of any law or of the character required
to be disclosed in the Prospectus; (ii) no relationship, direct or indirect, exists between or among the Company or, to the Company’s
knowledge, any affiliate of the Company, on the one hand, and the directors, officers and stockholders of the Company, that is required
by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii) no relationship,
direct or indirect, exists between or among the Company, or any affiliate of the Company, on the one hand, and the directors, officers,
stockholders or directors of the Company that is required by the rules of FINRA to be described in the Registration Statement and the
Prospectus that is not so described; (iv) there are no material outstanding loans or advances or material guarantees of indebtedness
by the Company to or for the benefit of any of its officers or directors or any of the members of the families of any of them; (v) the
Company has not offered, or caused any placement agent to offer, Common Stock to any person with the intent to influence unlawfully (A)
a customer or supplier of the Company to alter the customer’s or supplier’s level or type of business with the Company or
(B) a trade journalist or publication to write or publish favorable information about the Company or any of its products or services,
and, (vi) neither the Company nor, to the Company’s knowledge, any employee or agent of the Company has made any payment of funds
of the Company or received or retained any funds in violation of any law, rule or regulation (including, without limitation, the Foreign
Corrupt Practices Act of 1977, which payment, receipt or retention of funds is of a character required to be disclosed in the Registration
Statement or the Prospectus).

 

    	15

     

    

 

(qq)
Compliance with Applicable Laws. The Company has not been advised, and has no reason to believe, that it and each of its subsidiaries
are not conducting business in material compliance with all applicable laws, rules and regulations of the jurisdictions in which it is
conducting business, except where failure to be so in compliance would not reasonably be expected to result in a Material Adverse Effect.

 

(rr)
Status Under the Securities Act. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities
Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.

 

(ss)
No Misstatement or Omission in an Issuer Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and
as of each Applicable Time (as defined in Section 24 below), did not, does not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated
document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in
or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by
the Agent specifically for use therein.

 

(tt)
No Conflicts. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation
of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions hereof and
thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute
a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of
the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as may have been waived and (ii) such
conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x) in any violation of the
provisions of the organizational or governing documents of the Company, or (y) in any material violation of the provisions of any statute
or any order, rule or regulation applicable to the Company or of any court or of any federal, state or other regulatory authority or
other government body having jurisdiction over the Company.

 

    	16

     

    

 

(uu)
FCPA. Neither the Company nor any of its subsidiaries, any of the Company’s affiliates, any director, officer, nor, to the
knowledge of the Company, agent, employee or other person associated with or acting on behalf of the Company or any of its subsidiaries,
has in the course of its actions for, or on behalf of, the Company or any of its subsidiaries: (i) made any unlawful contribution, gift,
or other unlawful expense relating to political activity; (ii) made any direct or indirect bribe, kickback, rebate, payoff, influence
payment, or otherwise unlawfully provided anything of value, to any “foreign official” (as defined in the U.S. Foreign Corrupt
Practices Act of 1977, as amended (collectively, the “FCPA”)) or domestic government official; or (iii) violated or
is in violation of any provision of the FCPA, the Bribery Act 2010 of the United Kingdom, as amended (the “Bribery Act 2010”),
or any other applicable anti-corruption or anti-bribery statute or regulation. The Company and its subsidiaries and, to the knowledge
of the Company, the Company’s affiliates, have conducted their respective businesses in compliance with the FCPA, Bribery Act 2010
and all other applicable anti-corruption and anti-bribery statutes or regulations, and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to ensure, continued compliance therewith.

 

(vv)
Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the anti-money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or
similar rules, regulations or guidelines, that have been issued, administered or enforced by any governmental agency (collectively, the
“Anti-Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator or non-governmental authority involving the Company or any of its subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

(ww)
Sanctions. Neither the Company nor any of its subsidiaries, any of the Company’s affiliates, any director, officer, nor,
to the knowledge of the Company, agent, employee or affiliate of the Company or any of its subsidiaries is: (i) currently the subject
or the target of any sanctions administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department, the
U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions
authority (collectively, “Sanctions”); or (ii) located, organized or resident in a country or territory that is the
subject or target of Sanctions (including, without limitation, Cuba, Iran, North Korea, Syria and Crimea); and the Company will not directly
or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint
venture partner or other person or entity, for the purpose of financing or facilitating the activities of any person, or in any country
or territory, that at the time of such financing or facilitation and currently is the subject or target of Sanctions or in any other
manner that will result in a violation by any person (including any person participating in the transaction whether as an underwriter,
advisor, investor or otherwise) of Sanctions. The Company and its subsidiaries have not knowingly engaged in for the past five years,
are not now knowingly engaged in, and will not engage in, any dealings or transactions with any individual or entity, or in any country
or territory, that at the time of the dealing or transaction, is or was the subject or target of Sanctions.

 

    	17

     

    

 

(xx)
IT Systems. The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and Company
and its subsidiaries have taken all technical and organizational measures necessary to protect information technology and Personal Data
(as defined below) used in connection with, the operation of the business of the Company and its subsidiaries as currently conducted,
free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries
have implemented and maintained reasonable controls, policies, procedures, and safeguards to maintain and protect their confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including “personal data”
as defined by the EU General Data Protection Regulations (“GDPR”) (EU 2016 679) and any personal, personally identifiable,
household, sensitive, confidential or regulated data (“Personal Data”)) used in connection with their businesses,
except to the extent that a failure to do so could not reasonably be expected to have a Material Adverse Effect, and there have been
no breaches, violations, outages or unauthorized uses of or accesses to any IT System or Personal Data used in connection with the operation
of the Company’s and its subsidiaries’ businesses. The Company and its subsidiaries are presently in material compliance
with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory
authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to
the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.

 

(yy)
Privacy Laws. The Company and each of its subsidiaries are, and at all times during the past two years were, in compliance with
all applicable data privacy and security laws, statutes, judgements, orders, rules and regulations of any court or arbitrator or any
other governmental or regulatory authority and all applicable laws regarding the collection, use, transfer, export, storage, protection,
disposal or disclosure by the Company and its subsidiaries of Personal Data collected from or provided by third parties (collectively,
the “Privacy Laws”), except where the failure to be in compliance would not, individually or in the aggregate, result
in a Material Adverse Effect. The Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed
to (i) ensure compliance with its privacy policies, all third-party obligations and industry standards regarding Personal Data; and (ii)
reasonably protect the security and confidentiality of all Personal Data (collectively, the “Policies”). At all times
during the past two years, the Company has provided notice of its privacy policy on its websites, which provides accurate and sufficient
notice of Company’s then-current privacy practices relating to its subject matter and such privacy policies do not contain any
material omissions of the Company’s then-current privacy practices. None of such disclosures made or contained in the privacy policies
have been inaccurate, misleading, deceptive or in violation of any Privacy Laws or Policies in any material respect. To the knowledge
of the Company, the execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not
result in a breach of violation of any Privacy Laws or Policies. Neither the Company nor any subsidiary has received notice of any actual
or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws and is unaware of any other
facts that, individually or in the aggregate, would reasonably indicate non-compliance with any Privacy Laws or Policies. To the Company’s
knowledge, there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or threatened
alleging non-compliance with Privacy Laws or Policies.

 

(zz)
Stock Transfer Taxes. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid
or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with in all material respects.

 

    	18

     

    

 

(aaa)
Legal Entity Customer. The Company is not a “legal entity customer” for the purposes of 31 CFR § 1010.230(e).

 

Any
certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with
this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set
forth therein.

 

7.
Covenants of the Company. The Company covenants
and agrees with Agent that:

 

(a)
Registration Statement Amendments. After the date of this Agreement and during any period in which a Prospectus relating to any
Placement Shares is required to be delivered by the Agents under the Securities Act (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act) (the “Prospectus Delivery Period”) (i) the Company
will notify the Agents promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated
by reference, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been
filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional
information, (ii) the Company will prepare and file with the Commission, promptly upon the Agents’ request, any amendments or supplements
to the Registration Statement or Prospectus that, in the reasonable opinion of the Agents, may be necessary or advisable in connection
with the distribution of the Placement Shares by the Agents (provided, however, that the failure of the Agents to make
such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agents’ right to rely on the
representations and warranties made by the Company in this Agreement and provided, further, that the only remedy the Agents
shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement until such amendment or
supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus relating
to the Placement Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted to Agent within
a reasonable period of time before the filing and the Agents have not objected thereto (provided, however, that (A) the
failure of the Agents to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agents’
right to rely on the representations and warranties made by the Company in this Agreement and (B) the Company has no obligation to provide
the Agents any advance copy of such filing or to provide the Agents an opportunity to object to such filing if the filing does not name
the Agents or does not relate to the transaction herein provided; and provided, further, that the only remedy Agents shall
have with respect to the failure to by the Company to obtain such consent shall be to cease making sales under this Agreement) and the
Company will furnish to the Agents at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated
by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv) the Company will
cause each amendment or supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph
of Rule 424(b) of the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the Commission
as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement
with the Commission under this Section 7(a), based on the Company’s reasonable opinion or reasonable objections, shall be
made exclusively by the Company).

 

    	19

     

    

 

(b)
Notice of Commission Stop Orders. The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop
order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agents promptly after it receives
any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any
Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information
related to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.

 

(c)
Delivery of Prospectus; Subsequent Changes. During the Prospectus Delivery Period, the Company will comply with all requirements
imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all reports
and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a),
13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information
from the Registration Statement pursuant to Rule 430A under the Securities Act, it will use its commercially reasonable efforts to comply
with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430A and to notify the Agents promptly
of all such filings. If during the Prospectus Delivery Period any event occurs as a result of which the Prospectus as then amended or
supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in the light of the circumstances then existing, not misleading, or if during the Prospectus Delivery Period it is necessary to amend
or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify Agents to
suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement
or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance; provided,
however, that the Company may delay the filing of any amendment or supplement, if in the judgment of the Company, it is in the
best interests of the Company.

 

(d)
Listing of Placement Shares. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to
cause the Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such
jurisdictions as Agent reasonably designates and to continue such qualifications in effect so long as required for the distribution of
the Placement Shares; provided, however, that the Company shall not be required in connection therewith to qualify as a
foreign corporation or dealer in securities or file a general consent to service of process in any jurisdiction.

 

    	20

     

    

 

(e)
Delivery of Registration Statement and Prospectus. The Company will furnish to the Agents and their counsel (at the reasonable
expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein)
and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus
Delivery Period (including all documents filed with the Commission during such period that are deemed to be incorporated by reference
therein), in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably request
and, at the request of the Agents, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement
Shares may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus)
to the Agent to the extent such document is available on EDGAR.

 

(f)
Earnings Statement. The Company will make generally available to its security holders as soon as practicable, but in any event
not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period
that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.

 

(g)
Use of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”

 

(h)
Notice of Other Sales. Without the prior written consent of the Agents, the Company will not, directly or indirectly, offer to
sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire,
Common Stock during the period beginning on the date on which any Placement Notice is delivered to a Designated Agent hereunder and ending
on the second (2nd) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant
to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered
by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other “at the market”
or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock
(other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock,
warrants or any rights to purchase or acquire, Common Stock prior to the termination of this Agreement; provided, however,
that such restrictions will not be required in connection with the Company’s issuance or sale of (i) Common Stock, restricted stock
units, options to purchase Common Stock or Common Stock issuable upon the exercise of options, pursuant to any employee or director stock
option or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan
limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii) Common Stock issuable upon
conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the
Company available on EDGAR or otherwise in writing to the Agent, and (iii) Common Stock, or securities convertible into or exercisable
for Common Stock, offered and sold in a negotiated transaction to vendors, customers, strategic partners or potential strategic partners,
acquisition candidates or other investors conducted in a manner so as not to be integrated with the offering of Common Stock hereby.

 

(i)
Change of Circumstances. The Company will, at any time during the pendency of a Placement Notice advise the Agents promptly after
it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect
any opinion, certificate, letter or other document required to be provided to the Agents pursuant to this Agreement.

 

    	21

     

    

 

(j)
Due Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by the Agents or its
representatives in connection with the transactions contemplated hereby, including, without limitation, providing information and making
available documents and senior corporate officers, during regular business hours and at the Company’s principal offices, as the
Agents may reasonably request.

 

(k)
Required Filings Relating to Placement of Placement Shares. The Company agrees that on such dates as the Securities Act shall
require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the
Securities Act (each and every filing under Rule 424(b), a “Filing Date”), which prospectus supplement will set forth,
within the relevant period, the amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation
payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus
supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange
or market.

 

(l)
Representation Dates; Certificate. On the date of this Agreement and on or prior to the date in which the Company:

 

(i)
files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to
an offering of securities other than the Placement Shares), the Registration Statement or the Prospectus relating to the Placement Shares
by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration
Statement or the Prospectus relating to the Placement Shares;

 

(ii)
files an Annual Report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material
amendment to the previously filed Form 10-K);

 

(iii)
files a quarterly report on Form 10-Q under the Exchange Act; or

 

(iv)
files a current report on Form 8-K containing amended financial information (other than information “furnished” pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain
properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act;
(Each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a “Representation Date”)

 

    	22

     

    

 

the
Company shall furnish the Agents (but in the case of clause (iv) above only if the Agents reasonably determine that the information contained
in such Form 8-K is material) with a certificate, in the form attached hereto as Exhibit 7(l) (the “Representation Date Certificate”);
provided however, if no Placement Notice is pending at such Representation Date, then before the Company delivers a Placement
Notice or the Designated Agent sells any Placement Shares, the Company shall provide the Agents with a Representation Date Certificate.
The requirement to provide a Representation Date Certificate shall be waived for any Representation Date occurring at a time at which
no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice
hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; provided,
however, that such waiver shall not apply for any Representation Date on which the Company files its Annual Report on Form 10-K.
Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the
Company relied on such waiver and did not provide the Agent with a Representation Date Certificate, then before the Company delivers
the Placement Notice or the Designated Agent sells any Placement Shares, the Company shall provide the Agents with a Representation Date
Certificate, dated the date of the Placement Notice.

 

(m)
Legal Opinions. (a) On or prior to the delivery of the first Placement Notice and on our prior to each Representation date in
which the Company is obligated to deliver a Representation Date Certificate for which no waiver is applicable, the Company shall cause
to be furnished to the Agents (1) a written opinion and negative assurance letter of Olshan Frome Wolosky LLP (“Company Counsel”),
or other counsel satisfactory to the Agent, in form and substance satisfactory to the Agents and their counsel, (2) a written opinion
of Sklar Williams PLLC, Nevada counsel to the Company and (3) a written opinion of the Company’s General Counsel; provided however,
if no placement notice is pending at such Representation Date, then before the Company delivers a Placement Notice or the Designated
Agent sells any Placement Shares, the Company shall cause such opinions described in clauses (a)(1)-(3) to the Agents; provided,
further, that in lieu of such opinion or negative assurance letter for subsequent periodic filings under the Exchange Act, counsel
may furnish the Agents with a letter (a “Reliance Letter”) to the effect that the Agents may rely on a prior opinion
or negative assurance letter delivered under this Section 7(m)(1) to the same extent as if it were dated the date of such letter
(except that statements in such prior opinion or negative assurance letter shall be deemed to relate to the Registration Statement and
the Prospectus as amended or supplemented as of the date of the Reliance Letter) and (b) The Agents shall have received from Latham &
Watkins LLP, counsel for the Agents, such opinion or opinions, and delivered and dated on each date in which the Company is obligated
to deliver a Representation Date Certificate for which no waiver is applicable, with respect to the issuance and sale of the Placement
Shares, the Registration Statement and the Prospectus and other related matters as the Agents may reasonably require, and the Company
shall have furnished to such counsel such documents as they reasonably request for the purpose of enabling them to pass upon such matters.

 

(n)
Comfort Letter. (1) On or prior to the date of the first sale of the Placement Shares and (2) on or prior to each Representation
Date, with respect to which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(l) for which no
waiver is applicable, the Company shall cause its independent accountants and the SemaConnect Accountant to furnish the Agents letters
(the “Comfort Letters”), dated the date such Comfort Letters are delivered, which shall meet the requirements set
forth in this Section 7(n); provided however, if no placement notice is pending at such Representation Date, then before
the Company delivers a Placement Notice or the Designated Agent sells any Placement Shares, the Company shall provide the Agents with
the Comfort Letters; provided, further, that if requested by the Agents, the Company shall cause the Comfort Letters to
be furnished to the Agents on the date of occurrence of any event specified in (l)(iv) above (with such qualifications as provided therein),
including the restatement of the Company’s financial statements. The Comfort Letters from each of the Company’s independent
accountants and the SemaConnect Accountant shall be in a form and substance satisfactory to the Agents, (i) confirming that each is an
independent public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (the “PCAOB”),
(ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters
ordinarily covered by accountants’ “comfort letters” to underwriters in connection with registered public offerings
(the first such letters, the “Initial Comfort Letters”) and (iii) updating the Initial Comfort Letters with any information
that would have been included in the Initial Comfort Letters had it been given on such date and modified as necessary to relate to the
Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.

 

    	23

     

    

 

(o)
Market Activities. The Company and its controlled affiliates will not, directly or indirectly, (i) take any action designed to
cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock, or pay
anyone any compensation for soliciting purchases of the Placement Shares other than the Agents.

 

(p)
Investment Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not become,
at any time prior to the termination of this Agreement, an “investment company,” as such term is defined in the Investment
Company Act.

 

(q)
No Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in their capacity
as agents hereunder, neither the Agents nor the Company (including its agents and representatives, other than the Agents in their capacity
as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities
Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares
hereunder.

 

(r)
Sarbanes-Oxley Act. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal
accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP and including those policies and procedures that (i) pertain to
the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of
the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company’s
consolidated financial statements in accordance with GAAP, (iii) that receipts and expenditures of the Company are being made only in
accordance with management’s and the Company’s directors’ authorization, and (iv) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material
effect on its financial statements. The Company will use commercially reasonable efforts to maintain such controls and other procedures,
including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder
that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms,
including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including
its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure and to ensure that material information relating to the Company is made known to it by others
within the Company, particularly during the period in which such periodic reports are being prepared.

 

    	24

     

    

 

8.
Payment of Expenses. The Company will pay all
expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, filing, including any fees
required by the Commission, and printing of the Registration Statement (including financial statements and exhibits) as originally filed
and of each amendment and supplement thereto, in such number as the Agents shall deem necessary, (ii) the printing and delivery to the
Agents of this Agreement and such other documents as may be required in connection with the offering, purchase, sale, issuance or delivery
of the Placement Shares, (iii) the preparation, issuance and delivery of the certificates, if any, for the Placement Shares to the Agents,
including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon the sale, issuance
or delivery of the Placement Shares to the Agents, (iv) the fees and disbursements of the counsel, accountants and other advisors to
the Company, (v) the reasonable out-of-pocket expenses of the Agents, including fees and disbursements of counsel to the Agents up to
$100,000 (which amount shall include all fees and disbursements of such counsel described in clause (ix) below) and quarterly disbursements
of counsel to the Agents up to $15,000 per calendar quarter, (vi) the printing and delivery to the Agents of copies of any Permitted
Issuer Free Writing Prospectus (defined below) and the Prospectus and any amendments or supplements thereto in such number as the Agents
shall deem necessary, (vii) the preparation, printing and delivery to the Agents of copies of the blue sky survey and any Canadian “wrapper”
and any supplements thereto, in such number as the Agents shall deem necessary, (viii) the fees and expenses of the transfer agent and
registrar for the Common Stock, (ix) the fees and expenses incident to any review by FINRA of the terms of the sale of the Placement
Shares, including fees and expenses of counsel to the Agents, and (x) the fees and expenses incurred in connection with the listing of
the Placement Shares on the Exchange.

 

9.
Conditions to Agents Obligations. The obligations
of the Agents hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations
and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the
Agents of a due diligence review satisfactory to it in its reasonable judgment, and to the continuing satisfaction (or waiver by the
Agents in their sole discretion) of the following additional conditions:

 

(a)
Registration Statement Effective. The Registration Statement shall have become effective and shall be available for the sale of
all Placement Shares contemplated to be issued by any Placement Notice.

 

    	25

     

    

 

(b)
No Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement
or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of
any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for
sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that
makes any material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed to
be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement,
the Prospectus or documents so that, in the case of the Registration Statement, it will not contain any materially untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading
and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading.

 

(c)
No Misstatement or Material Omission. The Agents shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s reasonable opinion is material,
or omits to state a fact that in the Agent’s reasonable opinion is material and is required to be stated therein or is necessary
to make the statements therein not misleading.

 

(d)
Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission,
there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any
Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect, or a downgrading in
or withdrawal of the rating assigned to any of the Company’s securities (other than asset backed securities) by any rating organization
or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company’s
securities (other than asset backed securities), the effect of which, in the case of any such action by a rating organization described
above, in the reasonable judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have),
is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the
manner contemplated in the Prospectus.

 

(e)
Legal Opinion. The Agent shall have received the opinions of Company Counsel required to be delivered pursuant Section 7(m) on or before the date on which such delivery of such opinion is required pursuant to Section 7(m).

 

(f)
Comfort Letter. The Agents shall have received the Comfort Letters required to be delivered pursuant Section 7(n) on or
before the date on which such delivery of such Comfort Letters are required pursuant to Section 7(n).

 

(g)
Representation Certificate. The Agents shall have received the certificate required to be delivered pursuant to Section 7(l) on or before the date on which delivery of such certificate is required pursuant to Section 7(l).

 

    	26

     

    

 

(h)
Secretary’s Certificate. On the date of this Agreement, the Agents shall have received a certificate, signed on behalf of
the Company by its corporate Secretary, in form and substance satisfactory to the Agents and their counsel.

 

(i)
No Suspension. Trading in the Common Stock shall not have been suspended on the Exchange, and the Common Stock shall not have
been delisted from the Exchange.

 

(j)
Other Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company
shall have furnished to the Agents such appropriate further information, certificates and documents as the Agents may reasonably request.
All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company will furnish
the Agents with such conformed copies of such opinions, certificates, letters and other documents as the Agents shall reasonably request.

 

(k)
Securities Act Filings Made. All filings with the Commission required by Rule 424 under the Securities Act to have been filed
prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing
by Rule 424.

 

(l)
Approval for Listing. The Placement Shares shall either have been approved for quotation on the Exchange, subject only to notice
of issuance, or the Company shall have filed an application for quotation of the Placement Shares on the Exchange at, or prior to, the
issuance of any Placement Notice.

 

(m)
No Termination Event. There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant
to Section 12(a).

 

10.
Indemnification and Contribution.

 

(a)
Company Indemnification. The Company agrees to indemnify and hold harmless each Agent, its partners, affiliates, members, directors,
officers, employees and agents and each person, if any, who controls such Agent within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act as follows:

 

(i)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto),
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein
not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer
Free Writing Prospectus, the Prospectus (or any amendment or supplement thereto) or any materials or information provided to investors
by, or with the approval of, the Company in connection with the marketing of the offering of the Placement Shares, or the omission or
alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading;

 

    	27

     

    

 

(ii)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided
that (subject to Section 10(d) below) any such settlement is effected with the written consent of the Agents, which consent
shall not unreasonably be delayed or withheld; and

 

(iii)
against any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel), reasonably incurred
in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body,
commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement
or omission, to the extent that any such expense is not paid under (i) or (ii) above, provided, however, that this indemnity
agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission
or alleged untrue statement or omission made solely in reliance upon and in conformity with written information furnished to the Company
by the Agents expressly for use in the Registration Statement (or any amendment thereto), or in any related Issuer Free Writing Prospectus
or the Prospectus (or any amendment or supplement thereto).

 

(b)
Agent Indemnification. Each of the Agents agree, severally and not jointly, to indemnify and hold harmless the Company and its
directors and each officer of the Company who signed the Registration Statement, and each person, if any, who (i) controls the Company
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common
control with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section
10(a), as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the
Registration Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in
conformity with the Agent Information.

 

(c)
Procedure. Any party that proposes to assert the right to be indemnified under this Section 10 will, promptly after receipt
of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or
parties under this Section 10, notify each such indemnifying party of the commencement of such action, enclosing a copy of all
papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that
it might have to any indemnified party otherwise than under this Section 10 and (ii) any liability that it may have to any indemnified
party under the foregoing provision of this Section 10 unless, and only to the extent that, such omission results in the forfeiture
of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies
the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects
by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified
party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory
to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense,
the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below and except
for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified
party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will
be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing
by the indemnifying party, (2) the indemnified party has reasonably concluded (based on written advice of counsel) that there may be
legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying
party, (3) a conflict or potential conflict exists (based on written advice of counsel to the indemnified party) between the indemnified
party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on
behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action
within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements
and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party
or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all
such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly
after the indemnifying party receives a written invoice relating to fees, disbursements and other charges in reasonable detail. An indemnifying
party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying
party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment
in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 10 (whether or not
any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an unconditional release of each
indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement
as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

 

    	28

     

    

 

(d)
Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for
in the foregoing paragraphs of this Section 10 is applicable in accordance with its terms but for any reason is held to be unavailable
from the Company or the Agents, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages
(including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of,
any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other
than the Agents, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed
the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and the Agents
may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and
the Agents on the other hand. The relative benefits received by the Company on the one hand and the Agents on the other hand shall be
deemed to be in the same proportion as the total net proceeds from the sale of the Placement Shares (before deducting expenses) received
by the Company bear to the total compensation received by the Agents (before deducting expenses) from the sale of Placement Shares on
behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation
of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing
sentence but also the relative fault of the Company, on the one hand, and the Agents, on the other hand, with respect to the statements
or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant
equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to
information supplied by the Company or the Agents, the intent of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such statement or omission. The Company and the Agents agree that it would not be just and equitable
if contributions pursuant to this Section 10(d) were to be determined by pro rata allocation or by any other method of allocation
that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as
a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 10(d)
shall be deemed to include, for the purpose of this Section 10(d), any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action or claim to the extent consistent with Section 10(c)
hereof. Notwithstanding the foregoing provisions of this Section 10(d), no Agent shall not be required to contribute any amount
in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section 10(d), any person who controls a party to this Agreement within the meaning of
the Securities Act, and any officers, directors, partners, employees or agents of the Agents, will have the same rights to contribution
as that party, and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the
Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement
of any action against such party in respect of which a claim for contribution may be made under this Section 10(d), will notify
any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties
from whom contribution may be sought from any other obligation it or they may have under this Section 10(d) except to the extent
that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution
is sought. Except for a settlement entered into pursuant to the last sentence of Section 10(c) hereof, no party will be liable
for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section
10(c) hereof.

 

11.
Additional Covenants.

 

(a)
Representations and Covenants of the Agents. Each Agent, severally and not jointly, represents and warrants that it is duly registered
as a broker-dealer under FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares
will be offered and sold, except such states in which the Agent is exempt from registration or such registration is not otherwise required.
Each Agent shall continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and
the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such states in which
such Agent is exempt from registration or such registration is not otherwise required, during the term of this Agreement. Each Agent
shall comply with all applicable law and regulations in connection with the transactions contemplated by this Agreement, including the
issuance and sale through the Designated Agent of the Placement Shares.

 

    	29

     

    

 

(b)
Representations and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 10 of
this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive,
as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agents, any controlling persons, or the
Company (or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement Shares
and payment therefor or (iii) any termination of this Agreement.

 

12.
Termination.

 

(a)
The Agent may terminate this Agreement, by notice to the Company, as hereinafter specified at any time (1) if there has been, since the
time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material Adverse Effect,
or any development that is reasonably likely to have a Material Adverse Effect or, in the sole judgment of the Agent, is material and
adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement
Shares, (2) if there has occurred any material adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective
change in national or international political, financial or economic conditions, in each case the effect of which is such as to make
it, in the judgment of the Agent, impracticable or inadvisable to market the Placement Shares or to enforce contracts for the sale of
the Placement Shares, (3) if trading in the Common Stock has been suspended or limited by the Commission or the Exchange, or if trading
generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension
of trading of any securities of the Company on any exchange or in the over-the-counter market shall have occurred and be continuing,
(5) if a major disruption of securities settlements or clearance services in the United States shall have occurred and be continuing,
or (6) if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any such termination shall be without
liability of any party to any other party except that the provisions of Section 6 (Representations and Warranties of the Company),
Section 8 (Expenses), Section 10 (Indemnification), Section 11 (Survival of Representations), Section 17
(Governing Law; Consent to Jurisdiction) and Section 18 (Waiver of Jury Trial) hereof shall remain in full force and effect notwithstanding
such termination. If the Agent elects to terminate this Agreement as provided in this Section 12(a), the Agent shall provide the
required notice as specified in Section 13 (Notices).

 

(b)
The Company shall have the right, by giving written notice as hereinafter specified, to terminate this Agreement in its sole discretion
at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 6, Section 8, Section 10, Section 11, Section 17 and Section 18
hereof shall remain in full force and effect notwithstanding such termination.

 

    	30

     

    

 

(c)
Each of the Agents shall have the right, by giving written notice as hereinafter specified, to terminate this Agreement in its sole discretion
at any time after the date of this Agreement, with respect to such Agent only. Following any termination by an Agent, the Agreement shall
remain in effect as to each other Agent that has not exercised its right to terminate the provisions of this Agreement pursuant to this
Section 12(c) and any obligations and rights of the Agents under this Agreement shall be satisfied by or afforded to, as applicable,
only such other Agents that have not so terminated. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 6, Section 8, Section 10, Section 11, Section 17 and Section 18
hereof shall remain in full force and effect notwithstanding such termination.

 

(d)
Unless earlier terminated pursuant to this Section 12, this Agreement shall automatically terminate upon the issuance and sale
of all of the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; provided that the
provisions of Section 6, Section 8, Section 10, Section 11, Section 17 and Section 18 hereof
shall remain in full force and effect notwithstanding such termination.

 

(e)
This Agreement shall remain in full force and effect unless terminated pursuant to Sections 12(a), (b), (c), or
(d) above or otherwise by mutual agreement of the parties; provided, however, that any such termination by mutual
agreement shall in all cases be deemed to provide that Section 6, Section 8, Section 10, Section 11, Section
17 and Section 18 shall remain in full force and effect.

 

(f)
Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however,
that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent(s) or the
Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement
Shares shall settle in accordance with the provisions of this Agreement.

 

(g)
Subject to the additional limitations set forth in Section 8 of this Agreement, in the event of termination of this Agreement
prior to the sale of any Placement Shares, the Agents shall be entitled only to reimbursement of its out-of-pocket expenses actually
incurred.

 

13.
Notices. All notices or other communications
required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless
otherwise specified, and if sent to the Agents, shall be delivered to:

 

Barclays
Capital Inc.

745
Seventh Avenue

New
York, New York 10019

Attention:
robert.stowe@barclays.com

 

BofA
Securities, Inc.

One
Bryant Park

New
York, New York 10036

Attention:
ATM Execution Group, email: dg.atm_execution@bofa.com

 

HSBC
Securities (USA) Inc.

452
Fifth Avenue

New
York, New York 10018

Attention:
hsbcsharerepo@us.hsbc.com

 

    	31

     

    

 

H.C.
Wainwright & Co., LLC

430
Park Avenue

New
York, New York 10022

Attention:
Chief Executive Officer, email: notices@hcwco.com

 

Roth
Capital Partners, LLC

888
San Clemente Drive, Suite 400

Newport
Beach, CA 92660

Attention:
atmdesk@roth.com

 

ThinkEquity
LLC

17
State Street, 41st Floor

New
York, New York 10004

Attention:
Head of Investment Banking, notices@think-equity.com

 

and

 

Latham
& Watkins LLP

1271
Avenue of the Americas

New
York, NY 10020

Attn:
Benjamin Cohen

E-mail:
Benjamin.Cohen@lw.com

 

and
if to the Company, shall be delivered to:

 

Blink
Charging Co.

605
Lincoln Road, 5th Floor

Miami
Beach, Florida 33139

Attn:
Michael D. Farkas, Chairman and Chief Executive Officer

 

with
a copy to:

 

Olshan
Frome Wolosky LLP

1325
Avenue of the Americas, 15th Floor

New
York, New York 10019

Attn:
Spencer G. Feldman, Esq.

E-mail:
sfeldman@olshanlaw.com

 

Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally, by email or by verifiable
facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is
not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized
overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return
receipt requested, postage prepaid).

 

    	32

     

    

 

An
electronic communication (“Electronic Notice”) shall be deemed written notice for purposes of this Section 13
if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received
at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic
Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”)
which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.

 

14.
Successors and Assigns. This Agreement shall
inure to the benefit of and be binding upon the Company and the Agents and their respective successors and the affiliates, controlling
persons, officers and directors referred to in Section 10 hereof. References to any of the parties contained in this Agreement
shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights
or obligations under this Agreement without the prior written consent of the other party; provided, however, that any Agent
may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company’s consent.

 

15.
Adjustments for Stock Splits. The parties acknowledge
and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any stock split, stock dividend
or similar event effected with respect to the Placement Shares.

 

16.
Entire Agreement; Amendment; Severability. This
Agreement (including all schedules and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire
agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto
with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument
executed by the Company and the Agents. In the event that any one or more of the provisions contained herein, or the application thereof
in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall
be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms
and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but
only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with
the intent of the parties as reflected in this Agreement.

 

17.
GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL.
THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    	33

     

    

 

18.
CONSENT TO JURISDICTION. EACH PARTY HEREBY
IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN,
FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH
COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING
IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT,
ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS
IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS
AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY
LAW.

 

19.
Use of Information. The Agents may not use any
information gained in connection with this Agreement and the transactions contemplated by this Agreement, including due diligence, to
advise any party with respect to transactions not expressly approved by the Company.

 

20.
Counterparts. This Agreement may be executed
in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Delivery of an executed Agreement by one party to the other may be made by facsimile transmission. Counterparts may be delivered via
facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

21.
Effect of Headings. The section and Exhibit headings
herein are for convenience only and shall not affect the construction hereof.

 

22.
Permitted Free Writing Prospectuses. The Company
represents, warrants and agrees that, unless it obtains the prior consent of the Agents, and each Agent represents, warrants and agrees,
severally and not jointly, that, unless it obtains the prior consent of the Company, it has not made and will not make any offer relating
to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a “free writing
prospectus,” as defined in Rule 405, required to be filed with the Commission. Any such free writing prospectus consented to by
the Agent or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.”
The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an “issuer
free writing prospectus,” as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable
to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.

 

    	34

     

    

 

23.
Absence of Fiduciary Relationship. The Company
acknowledges and agrees that:

 

(a)
Each Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether or not the Agent has advised or is advising the Company on other matters, and the Agent has no obligation to the Company with
respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;

 

(b)
it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;

 

(c)
the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement
and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

 

(d)
it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from
those of the Company and the Agent has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship or otherwise; and

 

(e)
it waives, to the fullest extent permitted by law, any claims it may have against the Agent for breach of fiduciary duty or alleged breach
of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agent shall not have any liability
(whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any person asserting
a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect of the
Agent’s obligations under this Agreement and to keep information provided by the Company to the Agent and the Agent’s counsel
confidential to the extent not otherwise publicly-available.

 

24.
Research Analyst Independence. The Company acknowledges
that the Agents’ research analysts and research departments are required to be independent from their respective investment banking
divisions and are subject to certain regulations and internal policies, and that the Agents’ research analysts may hold views and
make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ
from the views of the Agent’s investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted
by law, any claims that the Company may have against each Agent with respect to any conflict of interest that may arise from the fact
that the views expressed by its independent research analysts and research departments may be different from or inconsistent with the
views or advice communicated to the Company by the Agent’s investment banking divisions. The Company acknowledges that the Agent
is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its
own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be
the subject of the transactions contemplated by this Agreement.

 

    	35

     

    

 

25.
Recognition of the U.S. Special Resolution Regimes.

 

(a)
In the event that any Agent that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as
the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
governed by the laws of the United States or a state of the United States.

 

(b)
In the event that any Agent that is a Covered Entity or a BHC Act Affiliate of such Agent becomes subject to a proceeding under a U.S.
Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Agent are permitted to be exercised
to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed
by the laws of the United States or a state of the United States.

 

(c)
As used in this Agreement:

 

(i)
“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted
in accordance with, 12 U.S.C. § 1841(k).

 

(ii)
“Covered Entity” means any of the following:

 

	 	a.	“covered
    entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
	 	 	 
	 	b.	a
    “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
	 	 	 
	 	c.	a
    “covered FSI” as that term is defined in, and interpreted in accordance with 12 C.F.R. § 382.2(b).

 

(iii)
“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
§§ 252.81, 47.2 or 382.1, as applicable.

 

(iv)
“U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

 

    	36

     

    

 

26.
Definitions. As used in this Agreement, the following
terms have the respective meanings set forth below:

 

“Applicable
Time” means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement, and
(iii) each Settlement Date.

 

“Business
Day” shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

 

“Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to the Placement
Shares that (1) is required to be filed with the Commission by the Company, (2) is a “road show” that is a “written
communication” within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt
from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.

 

“Rule
172,” “Rule 405,” “Rule 415,” “Rule 424,” “Rule 424(b),”
“Rule 430B,” and “Rule 433” refer to such rules under the Securities Act.

 

“Trading
Day” means any day on which shares of Common Stock are purchased and sold on the Exchange.

 

All
references in this Agreement to financial statements and schedules and other information that is “contained,” “included”
or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration
Statement or the Prospectus, as the case may be.

 

All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission)
shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to “supplements”
to the Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials prepared in connection
with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.

 

If
the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below
for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agents.

 

[Signature
pages follow]

 

    	37

     

    

 

	 	Very
    truly yours,
	 	 
	 	BLINK
    CHARGING CO.
	 	 	 
	 	By:	/s/
    Michael D. Farkas
	 	Name:	Michael
    D. Farkas
	 	Title:	Chairman
    and CEO

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

	 	ACCEPTED
    as of the date first-above written:
	 	 
	 	BARCLAYS
    CAPITAL INC.
	 	 	           
	 	By:	/s/
    Robert Stowe
	 	Name:	Robert
    Stowe
	 	Title:	Managing
    Director

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

	 	ACCEPTED
    as of the date first-above written:
	 	 
	 	BofA
    Securities, Inc.
	 	 	             
	 	By:	/s/ Mark J. Doller
	 	Name:	Mark
    J. Doller
	 	Title:	Managing
    Director

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

	 	ACCEPTED
    as of the date first-above written:
	 	 
	 	HSBC
    Securities (USA) Inc.
	 	 	           
	 	By:	/s/
    Jeff Nicklas
	 	Name:	Jeff
    Nicklas
	 	Title:	Managing
    Director

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

	 	ACCEPTED
    as of the date first-above written:
	 	 
	 	H.C.
    Wainwright & Co., LLC
	 	 	                
	 	By:	/s/
    Edward D. Silvera
	 	Name:	Edward
    D. Silvera
	 	Title:	Chief
    Operating Officer

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

	 	ACCEPTED
    as of the date first-above written:
	 	 
	 	Roth
    Capital Partners, LLC
	 	 	           
	 	By:	/s/
    Aaron M. Gurewitz
	 	Name:	Aaron
    M. Gurewitz
	 	Title:	Head
    of Equity Capital Markets

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

	 	ACCEPTED
    as of the date first-above written:
	 	 
	 	ThinkEquity
    LLC
	 	 	                
	 	By:	/s/
    Kevin Mangan
	 	Name:	Kevin
    Mangan
	 	Title:	Managing
    Director, Head of Equity Syndicate

 

[Signature
pages to Sales Agreement]

 

    	 

     

    

 

SCHEDULE
1

 

FORM
OF PLACEMENT NOTICE

 

	From:	BLINK
    CHARGING CO.
	 	 
	To:	BARCLAYS
    CAPITAL INC.
	 	BofA
    Securities, Inc.
	 	HSBC
    Securities (USA) Inc.
	 	H.C.
    Wainwright & Co., LLC
	 	Roth
    Capital Partners, LLC
	 	ThinkEquity
    LLC
	 	 
	Attention:	 
	 	 
	Subject:	Placement
    Notice
	 	 
	Date:	 
	 	 
	Gentlemen:	 

 

Pursuant
to the terms and subject to the conditions contained in the Sales Agreement between, Blink Charging Co. (the “Company”)
and Barclays Capital Inc., BofA Securities, Inc., HSBC Securities (USA) Inc., H.C. Wainwright & Co., LLC, Roth Capital Partners,
LLC and ThinkEquity LLC (each an “Agent” and together the “Agents”), dated September 2, 2022, the
Company hereby requests that the Agents sell up to ____________ of the Company’s Common Stock, $0.001 par value per share, at a
minimum market price of $_______ per share, during the time period beginning [month, day, time] and ending [month, day, time].

 

    	 

     

    

 

SCHEDULE
2

 

Compensation

 

The
Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount up to 3% of the gross
proceeds from each sale of Placement Shares.

 

    	 

     

    

 

SCHEDULE
3

 

Notice
Parties

 

The
Company

 

Michael
D. Farkas

 

Michael
Rama

 

The
Agents

 

Barclays
Capital Inc.: Rory Elliot, Andy Levin

 

Bofa
Securities, Inc.: ATM Execution Group (dg.atm_execution@bofa.com)

 

HSBC
Securities (USA) Inc.: Jeff Nicklas

 

H.C.
Wainwright & Co., LLC: Craigh Scwabe

 

Roth
Capital Partners, LLC: Brian Kremer, Lou Ellis, Nazan Akdeniz, with a copy to RothECM@roth.com

 

ThinkEquity
LLC: William Baquet, with a copy to DealTeam@think-equity.com, Notices@think-equity.com, pq@think-equity.com, and dh@think-equity.com

 

    	 

     

    

 

EXHIBIT
7(l)

 

Form
of Representation Date Certificate

 

____________________,
20__

 

This
Representation Date Certificate (this “Certificate”) is executed and delivered in connection with Section 7(l)
of the Sales Agreement (the “Agreement”), dated September 2, 2022, and entered into between Blink Charging Co.
(the “Company”), Barclays Capital Inc., BofA Securities, Inc., HSBC Securities (USA) Inc., H.C. Wainwright & Co.,
LLC, Roth Capital Partners, LLC and ThinkEquity LLC. All capitalized terms used but not defined herein shall have the meanings given
to such terms in the Agreement.

 

The
undersigned, a duly appointed and authorized officer of the Company, having made all necessary inquiries to establish the accuracy of
the statements below and having been authorized by the Company to execute this certificate, hereby certifies as follows:

 

	1.	As
    of the date of this Certificate, (i) the Registration Statement does not contain any untrue statement of a material fact or omit
    to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and (ii)
    neither the Registration Statement nor the Prospectus contain any untrue statement of a material fact or omit to state a material
    fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
    they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement the Prospectus
    in order to make the statements therein not untrue or misleading.
	 	 
	2.	Each
    of the representations and warranties of the Company contained in the Agreement were, when originally made, and are, as of the date
    of this Certificate, true and correct in all respects.
	 	 
	3.	Each
    of the covenants required to be performed by the Company in the Agreement on or prior to the date of the Agreement, this Representation
    Date, and each such other date as set forth in the Agreement, has been duly, timely and fully performed in all material respects
    and each condition required to be complied with by the Company on or prior to the date of the Agreement, this Representation Date,
    and each such other date as set forth in the Agreement or in the Waivers has been duly, timely and fully complied with in all material
    respects.
	 	 
	4.	Subsequent
    to the date of the most recent financial statements in the Prospectus, there has been no Material Adverse Effect.
	 	 
	5.	No
    stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and no proceedings
    for that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including,
    without limitation, the Commission).

 

The
undersigned has executed this Representation Date Certificate as of the date first written above.

 

	 	BLINK
    CHARGING CO.
	 	 	          
	 	By:	 
	 	Name:	 
	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]